Promore Pharma
Promore Pharma: Mixed data (continued) (Redeye)
2020-12-02 08:35
Redeye lowers its valuation of Promore Pharma (base case at SEK 6) following mixed study data from its phase IIb trial.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se